期刊文献+

拉氧头孢钠合成工艺的改进

Synthesis of Latamoxef Disodium
下载PDF
导出
摘要 以7β-氨基-7α-甲氧基-3-(1-甲基-5-四唑基)硫甲基-1-氧杂去硫杂-3-头孢烯-4-羧基二苯甲酯,经缩合反应,再用四氯化钛脱羧基保护,最终用异辛酸钠成盐,溶剂法得拉氧头孢钠,总收率约81.4%。 Latamoxef disodium was prepared from 7β-amino-7α-methoxy-3-(1-methyl-5-tetrazolyl)sulfanylmethyl-1-oxo-3-cephem-4-carboxyldiphenylmethylest-er,after condensation reaction,hydrolysis with titanium tetrachloride,and final-y salt with sodium isooctanoate,and solvent method to obtain latamoxet disodi-um,with an overall yield of about 81.4%.
作者 卢峻 王小平 Lu Jun;Wang Xiaoping(Zhejiang Dongbang Pharmaceutical Co.,Ltd.,Linhai 317000,China)
出处 《山东化工》 CAS 2021年第5期59-60,共2页 Shandong Chemical Industry
关键词 拉氧头孢钠 工艺改进 合成 latamoxef disodium process improvement synthesis
  • 相关文献

参考文献1

二级参考文献20

  • 1张凤凯,李家泰,潘石,郝凤兰,陈杨.拉氧头孢对临床分离的1143株致病菌体外抗菌作用的研究[J].中国抗生素杂志,1994,19(3):221-229. 被引量:6
  • 2Clinical and Laboratory Standards Institute. Methods for Di lution Antimicrobial Susceptibility Tests for Bacteria That Glow Aerobically [S]. Approved Standard Eighth Edition, 2009, M07-A8.
  • 3Clinical and Laboratory Standards Institute. Methods for An- timicrobial Susceptibility Testing of Anaerobic Bacteria[S]. Approved Standard-Seventh Edition, 2007, M1 l-A7.
  • 4Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing[S]. Twenty-Second Informational Supplement, 2012, M100-S22.
  • 5Jones RN, Barry AL, Packer RR, et al. In vitro antimicrobi- al spectrum, accurrence of synergy, and recommendations for dilution susceptibility testing concentration of the cefopera- zone-sulbactam combination[J]. J Clin Microbiol, 1987,25 (9): 1725-1729.
  • 6P6rez-P6rez F J, Hanson ND. Detection of plasmid-mediated AmpC beta lactamase genes in clinical isolates by using multi- plex PCR[J]. J Clin Microbiol, 2002, 40(6): 2153 -2162.
  • 7Snepar R, Poporad G, Romano J, et al. In vitro activity, ef- ficacy, and pharmacology of moxalactam, a new beta-lactam antibiotic[J]. Antimicrob Agents Chemother , 1981,20 (5) : 642-647.
  • 8Reimer LG, Mirrett S, Reller LB. Comparison of in vitro ac- tivity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates[J]. Antimicrob Agents Chemoth er, 1980, 17 (3):412-416.
  • 9Lang SD, Edwards DJ, Durack DT. Comparison of cefopera- zone, cefotaxime, and moxalactam (LY127935) against aero- bic gram-negative bacilli[J]. Antimicrob Agents Chemother, 1980, 17 (3) :488-493.
  • 10Paterson DL, Bonomo RA. Extended spectrum beta-lactama- ses: a clinical update[J]. Clin Microbiol Rev, 2005,18(4): 657-686.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部